Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Simeone, Ester ^a   Grimaldi, Antonio Maria ^a   Festino, Lucia ^a   Giannarelli, Diana ^b   Vanella, Vito ^a   Palla, Marco ^a   Curvietto, Marcello ^a   Esposito, Assunta ^a   Palmieri, Giuseppe ^a   Mozzillo, Nicola ^a   Ascierto, Paolo Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anti PD 1 antibodies; BRAF inhibitors; immunotherapy; melanoma; pembrolizumab

Indexed keywords

B RAF KINASE; DABRAFENIB; IPILIMUMAB; LACTATE DEHYDROGENASE; PEMBROLIZUMAB; VEMURAFENIB;

ADULT; ARTICLE; CANCER INHIBITION; CANCER STAGING; CLINICAL ARTICLE; ECOG PERFORMANCE STATUS; FEMALE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MALE; MELANOMA; METASTASIS; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

EID: 85014465478     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1283462     Document Type: Article

References (23)

1. Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer 2014; 120:1695-701; PMID:24577748; http://dx.doi.org/10.1002/cncr.28620
2. Ascierto PA, Long GV. Progression-free survival landmark analysis:a critical endpoint in melanoma clinical trials. Lancet Oncol 2016; 17:1037-9; PMID:27324281; http://dx.doi.org/10.1016/S1470-2045(16)30017-1
3. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM):updated efficacy results from a randomized, double-blind, phase 3 trial. Lancet Oncol 2016; 17:1248-60; PMID:27480103; http://dx.doi.org/10.1016/S1470-2045(16)30122-X
4. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma:a possible algorithm for clinical use. J Transl Med 2012; 10:107; PMID:22640478; http://dx.doi.org/10.1186/1479-5876-10-107
5. Ascierto PA, Simeone E, Grimaldi AM, Curvietto M, Esposito A, Palmieri G, Mozzillo N. Do BRAF inhibitors select for populations with different disease progression kinetics? J Transl Med 2013; 11:61; PMID:23497384; http://dx.doi.org/10.1186/1479-5876-11-61
6. Ascierto PA, Simeone E, Sileni VC, Del Vecchio M, Marchetti P, Cappellini GC, Ridolfi R, de Rosa F, Cognetti F, Ferraresi V, et al. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma:data from the Italian cohort of the ipilimumab expanded access program. Cancer Invest 2014; 32:144-9; PMID:24484235; http://dx.doi.org/10.3109/07357907.2014.885984
7. Atkinson V, Ascierto PA, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, et al. Two-year survival and safety update in patients (pts) with treatment-naïve advanced melanoma (MEL) receiving nivolumab (NIVO) or dacarbazine (DTIC) in CheckMate 066. J Transl Med 2016; 14(Suppl 1):S65 (abstract O9)
8. Daud A, Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, Weber JS, Gangadhar TC, Joseph RW, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2015; 33:(suppl; abstr 9005)
9. Hwu P, Hamid O, Gonzalez R, Infante JR, Patel MR, Hodi F, Lewis KD, Wallin J, Mwawasi G, Cha E, et al. Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma. Ann Oncol 2016; 27:379-400
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
11. Lau PK, Ascierto PA, McArthur G. Melanoma:the intersection of molecular targeted therapy and immune checkpoint inhibition. Curr Opin Immunol 2016; 39:30-8; PMID:26765776; http://dx.doi.org/10.1016/j.coi.2015.12.006
12. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma:a multicentre, double-blind, phase 3 randomized controlled trial. Lancet 2015; 386:444-51; PMID:26037941; http://dx.doi.org/10.1016/S0140-6736(15)60898-4
13. V600 mutation status and prior BRAF inhibitor therapy. Pigment Cell Melanoma Res J 2015; 392-3.
14. Ribas A, Butler M, Lutzky J, Lawrence DP, Robert C, Miller W, Linette GP, Ascierto PA, Kuzel T, Algazi AP, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. J Clin Oncol 2015; 33:1865-6; (suppl; abstr 3003); PMID:25667273; http://dx.doi.org/10.1200/JCO.2014.59.5041
15. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368:1365-6; PMID:23550685; http://dx.doi.org/10.1056/NEJMc1302338
16. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroyakovskiy D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib and trametinib versus vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. In:Abstract presented at the Euro Cancer Congress, September28, 2015, 2015; Abstract 3301.
17. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil CM, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma:final overall survival analysis of KEYNOTE-006. J Clin Oncol 2016; 34 (suppl; abstr 9504)
18. Sullivan R, Hamid O, Patel M, Hodi S, Amaria R, Boasberg P, Wallin J, He X, Cha E, Richie N, et al. Preliminary clinical safety, tolerability and activity results from a Phase Ib study of atezolizumab (anti-PDL1) combined with vemurafenib in BRAFV600-mutant metastatic melanoma. J Transl Med 2016, 14(Suppl 1):S65 (abstract O6)
19. Wargo J, Cooper Z, Flaherty K. Universes collide:combining immunotherapy with targeted therapy for cancer. Cancer Discov 2014; 4:1377-86; PMID:25395294; http://dx.doi.org/10.1158/2159-8290.CD-14-0477
20. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037):a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8
21. Wilmott J, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-94; PMID:22156613; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479
22. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors:immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624
23. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369